Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle

被引:142
作者
Kim, Jin Kyeoung [2 ]
Choi, Kyung-Ju [1 ]
Lee, Minhyung [3 ]
Jo, Mi-hee [1 ]
Kim, Soonhag [1 ]
机构
[1] CHA Univ, Coll Life Sci, Dept Biomed Sci, Lab Mol Imaging, Seoul 135907, South Korea
[2] CHA Univ, Coll Pharm, Dept Pharm, Gyeonggi Do 487010, South Korea
[3] Hanyang Univ, Coll Engn, Dept Bioengn, Seoul 133791, South Korea
基金
新加坡国家研究基金会;
关键词
Aptamer; microRNA-221; Theragnostics; Molecular beacon; Multimodal nanoparticles; Cancer targeting; MESSENGER-RNA EXPRESSION; IN-VIVO; QUANTUM DOTS; KAPPA-B; CELLS; BIOGENESIS; DELIVERY; MIRNAS; SYSTEM; GENE;
D O I
10.1016/j.biomaterials.2011.09.023
中图分类号
R318 [生物医学工程];
学科分类号
100103 [病原生物学];
摘要
MicroRNAs (miRNA, miR) have been reported as cancer biomarkers that regulate tumor suppressor genes. Hence, simultaneous detecting and inhibiting of miRNA function will be useful as a cancer theragnostics probe to minimize side effects and invasiveness. In this study, we developed a cancer-targeting therangostics probe in a single system using an AS1411 aptamer - and miRNA-221 molecular beacon (miR-221 MB)-conjugated magnetic fluorescence (MF) nanoparticle (MFAS miR-221 MB) to simultaneously target to cancer tissue, image intracellularly expressed miRNA-221 and treat miRNA-221-involved carcinogenesis. AS1411 aptamer-conjugated MF (MFAS) nanoparticles displayed a great selectivity and delivery into various cancer cell lines. The miR-221 MB detached from the MFAS miR-221 MB in the cytoplasm of C6 cells clearly imaged miRNA-221 biogenesis and simultaneously resulted in antitumor therapeutic effects by inhibiting miRNA function, indicating a successful astrocytoma-targeting theragnostics. MFAS miRNA MB can be easily applied to other cancers by simply changing a targeted miRNA highly expressed in cancers. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:207 / 217
页数:11
相关论文
共 44 条
[1]
Biosensing with plasmonic nanosensors [J].
Anker, Jeffrey N. ;
Hall, W. Paige ;
Lyandres, Olga ;
Shah, Nilam C. ;
Zhao, Jing ;
Van Duyne, Richard P. .
NATURE MATERIALS, 2008, 7 (06) :442-453
[2]
MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[3]
Nuclear factor-kappa B and cancer: its role in prevention and therapy [J].
Bharti, AC ;
Aggarwal, BB .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (5-6) :883-888
[4]
MiRNAs in cancer: approaches, aetiology, diagnostics and therapy [J].
Blenkiron, Cherie ;
Miska, Eric A. .
HUMAN MOLECULAR GENETICS, 2007, 16 :R106-R113
[5]
Nanoparticles with Raman spectroscopic fingerprints for DNA and RNA detection [J].
Cao, YWC ;
Jin, RC ;
Mirkin, CA .
SCIENCE, 2002, 297 (5586) :1536-1540
[6]
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells [J].
Chan, JA ;
Krichevsky, AM ;
Kosik, KS .
CANCER RESEARCH, 2005, 65 (14) :6029-6033
[7]
Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery [J].
Chen, XY ;
Plasencia, C ;
Hou, YP ;
Neamati, N .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) :1098-1106
[8]
MicroRNA-21 knockdown disrupts glioma growth In vivo and displays synergistic cytotoxicity with neural precursor cell-delivered S-TRAIL in human gliomas [J].
Corsten, Maarten F. ;
Miranda, Rafael ;
Kasmieh, Randa ;
Krichevsky, Anna M. ;
Weissleder, Ralph ;
Shah, Khalid .
CANCER RESEARCH, 2007, 67 (19) :8994-9000
[9]
miRNAs, cancer, and stem cell division [J].
Croce, CM ;
Calin, GA .
CELL, 2005, 122 (01) :6-7
[10]
Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRITR) [J].
De Santis, R ;
Anastasi, AM ;
D'Alessio, V ;
Pelliccia, A ;
Albertoni, C ;
Rosi, A ;
Leoni, B ;
Lindstedt, R ;
Petronzelli, F ;
Dani, M ;
Verdoliva, A ;
Ippolito, A ;
Campanile, N ;
Manfredi, V ;
Esposito, A ;
Cassani, G ;
Chinol, M ;
Paganelli, G ;
Carminati, P .
BRITISH JOURNAL OF CANCER, 2003, 88 (07) :996-1003